Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression

NCT04610528 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT04610528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04610528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Phase 1
Overall status
Unknown status
Start date
December 22, 2020
Completion date
September 30, 2023
Enrollment
80 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer